Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

Hepatology

Volumn 49, Issue 4, 2009, Pages 1245-1256

  Mejias, Marc ^a   Garci Pras, Ester ^a   Tiani, Carolina ^a   Miquel, Rosa ^b   Bosch, Jaime ^a   Fernandez, Mercedes ^a  

^a Liver Unit   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; PLATELET DERIVED GROWTH FACTOR; RAF PROTEIN; SORAFENIB; VASCULOTROPIN; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPLANCHNIC BLOOD FLOW; TISSUE REPAIR; VASODILATATION; VEIN LIGATION; ANGIOGENESIS; ANIMAL; COLLATERAL CIRCULATION; DRUG EFFECT; ENTERITIS; HEPATITIS; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BENZENESULFONATES; COLLATERAL CIRCULATION; ENTERITIS; HEME OXYGENASE-1; HEPATITIS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION;

EID: 65449130742     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22758     Document Type: Article

References (37)

1. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1-13.
2. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: Shades of grey. The case for nonselective beta blockers. Gastroenterology 2007;133:2029-2036.
3. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996;87:1153-1155.
4. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004;126:886-894.
5. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005;43:98-103.
6. Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol 2006;44:1033-1039.
7. Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperemia in portal hypertensive rats. Gut 2007;56:560-564.
8. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and plateletderived growth factor blockade in rats.HEPATOLOGY 2007;46:1208-1217.
9. Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med 2008;12: 1690-1699.
10. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
13. Fernandez M, Garcia-Pagan JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology 1995;108:1487-1495.
14. Fernandez M, Pizcueta P, Garcia-Pagan JC, Feu F, Cirera I, Bosch J, et al. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. HEPATOLOGY1993;18:389-393.
15. Franco D, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction. Arch Surg 1979;114:1064-1067.
16. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
17. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. HEPATOLOGY 2002;35:478-491.
18. Fernandez M, Bonkovsky HL. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. HEPATOLOGY1999;29:1672-1679.
19. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of plateletderived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 1989;84: 1786-1793.
20. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte? HEPATOLOGY2007; 45:817-825.
21. Biecker E, De Gottardi A, Neef M, Unternährer M, Schneider V, Ledermann M, et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: Analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005;313:952-961.
22. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006;45:786-796.
23. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.HEPATOLOGY2007; 46:1919-1926.
24. Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988;19:183-191.
25. Albillos A, de la Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004;363:1608-1610.
26. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. Platelet-derived growth factor signaling through ephrin-B2 regulates hepatic vascular structure and function. Gastroenterology 2008;135:671-679.
27. Brodsky S, Mendelev N, Melamed M, Ramaswamy G. Vascular density and VEGF expression in hepatic lesions. J Gastrointestin Liver Dis 2007; 16:373-377.
28. Xu H, Shi BM, Lu XF, Liang F, Jin X, Wu TH, et al. Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats. World J Gastroenterol 2008;14:2349-2357.
29. Tanaka A, Tsuneyama K, Mikami M, Uegaki S, Aiso M, Takikawa H. Gene expression profiling in whole liver of bile duct ligated rats: VEGF-A expression is up-regulated in hepatocytes adjacent to the portal tracts. J Gastroenterol Hepatol 2007;22:1993-2000.
30. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-345.
31. Medina J, Caveda L, Sanz-Cameno P, Arroyo AG, Martin-Vilchez S, Majano PL, et al. Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J Hepatol 2003;38:660-667.
32. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension.HEPATOLOGY 1993;17:1081-1085.
33. Navasa M, Forns X, Sanchez V, Andreu H, Marcos V, Borras JM, et al. Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrosis after liver transplantation. J Hepatol 1996;25:129-134.
34. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-1393.
35. Escorsell A, Bosch J. Pathophysiology of variceal bleeding. In: Groszmann RJ, Bosch J, eds. Portal Hypertension in the 21st Century. Kluwer Academic Publishers: Dordrecht, The Netherlands, 2004:155-166.
36. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. HEPATOLOGY2003;37:902-908.
37. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrosis: A systematic review. Gastroenterology 2006;131:1611-1624.